PO.PS01.06 · 人群科学
年轻肺癌患者的膳食模式:突变特异性环境关联
Dietary patterns in young lung cancer: mutation-specific environmental associations
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
在20世纪80年代中期烟草使用高峰之后,男性肺癌发病率大幅下降,而女性中未见这一现象。年轻时罹患肺癌现在在女性中比男性更常见,逆转了持续数十年的模式。我们试图刻画年轻肺癌患者的环境暴露,以了解年轻肺癌患者流行病学特征这一变化的潜在驱动因素。我们分析了来自年轻肺癌流行病学(Epidemiology of Young Lung Cancer, YLC)研究(ClinicalTrials.gov标识符:NCT04640259)的187例患者(157例女性,84%),采用基于共同生物学机制的突变分组:EGFR通路(EGFR+ERBB2)、融合阳性(ALK+ROS1+RET+NTRK)和其他/混合突变(包括MET外显子14跳跃、TP53、KRAS、BRAF及其他改变)。其中166例患者(138例女性,83.1%)完成了经验证的食物频率问卷。使用2015健康饮食指数(Healthy Eating Index-2015, HEI-2015)评估膳食质量,并与来自NHANES的美国参考值进行比较。利用已发表文献识别出污染物残留潜力升高的膳食类别。统计比较采用针对参考均值的单样本t检验和针对分类变量的卡方检验。EGFR组和ALK组分别有32.8%和13.4%的患者有烟草使用史。所有组中女性口服避孕药暴露水平均相似地较高(75-100%)。膳食分析显示,EGFR通路、融合阳性和其他/混合突变患者的HEI-2015评分(满分100)分别为64.9 ± 10.7、65.5 ± 9.8和63.5 ± 9.5,而美国参考值为58。YLC女性表现出比男性更高的膳食质量评分(65.6 ± 9.7 vs. 61.8 ± 11.3),两者均超过女性60和男性56的美国参考值。这些YLC患者还摄入了更多来自与污染物暴露潜力升高相关膳食类别的食物,这反映在总蔬菜(4.2 vs. 3.5)、水果(3.3 vs. 2.5)和全谷物(3.9 vs. 2.6)的更高HEI-2015成分评分(满分5)上。YLC患者具有更高膳食质量的饮食模式,全水果、蔬菜和全谷物的暴露更高。虽然这些食物组被认为具有良好的健康益处,但一个新兴且未受充分重视的文献表明,以农产品为基础的全食物往往含有高农药/除草剂污染物。及时进一步研究农药污染的水果/蔬菜/全谷物的作用,以评估其在过去四十年间不断变化的肺癌患病率中是否发挥作用(如有)。
查看英文原文 English abstract
Following peak tobacco incidence in the mid-1980's there has been a large reduction in lung cancer incidence among men that has not been seen among women. Lung cancer at a young age is now more common among women than men, reversing a decades long pattern. We sought to characterize environmental exposures among young lung cancer patients to understand potential drivers of this change in the epidemiologic profile of young lung cancer patients. We analyzed 187 patients (157 females, 84%) from the Epidemiology of Young Lung Cancer (YLC) study (ClinicalTrials.gov identifier: NCT04640259) using mutation-based grouping by shared biological mechanisms: EGFR Pathway (EGFR+ERBB2), Fusion Positive (ALK+ROS1+RET+NTRK), and Other/Mixed Mutations (including MET exon 14 skipping, TP53, KRAS, BRAF, and additional alterations). Of these, 166 patients (138 females, 83.1%) completed validated food frequency questionnaires. Dietary quality was assessed using the Healthy Eating Index-2015 (HEI-2015) and compared to U.S. reference values from NHANES. Dietary categories with elevated contaminant residue potential were identified using published literature. Statistical comparisons employed one-sample t-tests against reference means and chi-square tests for categorical variables. The EGFR groups and ALK groups had tobacco use history in 32.8% and 13.4% of patients respectively. All groups had similarly high levels of oral contraceptive exposure among women (75-100%). Dietary analysis revealed that EGFR Pathway, Fusion Positive, and Other/Mixed Mutations patients demonstrated HEI-2015 scores (out of 100) of 64.9 ± 10.7, 65.5 ± 9.8, and 63.5 ± 9.5 respectively, compared with the US reference of 58. YLC women demonstrated higher dietary quality scores than men (65.6 ± 9.7 vs. 61.8 ± 11.3), both exceeded U.S. reference values of 60 for females and 56 for males. These YLC patients also consumed more foods from dietary categories associated with elevated contaminant exposure potential, as reflected by higher HEI-2015 component scores (out of 5) for total vegetables (4.2 vs. 3.5), fruits (3.3 vs. 2.5), and whole grains (3.9 vs. 2.6). YLC patients have a diet pattern of higher diet quality, with higher exposure to whole fruits, vegetables and whole grains. While these food groups are presumed to have good health benefits, there is an emerging, under-appreciated literature that produce based whole foods often contain high pesticide/herbicide contaminants. Further investigation of the role of pesticide contaminated fruits/vegetables/whole grains is timely to assess its role, if any, in the changing lung cancer prevalence over the last 4 decades.
利益披露 Disclosure
S. D. Gorbatov, None..
M. A. Bittoni, None..
A. H. Wu, None..
A. Harper, None..
K. Virginia, None..
N. Florez, None.
B. J. Gitlitz,
Genentech Employment, Stock.
J. J. Nieva,
Aadi Biosciences Other, Consulting.
Novartis Stock.
ANP Technologies Other, Consulting.
AstraZeneca Other, Consulting.
BioAtla Other, Consulting.
BMS Other, Consulting.
Catalym Other, Consulting.
Gilead Other, Consulting.
Genentech ), Other, Consulting.
Pfizer Other, Consulting.
Kalivir Other, Consulting.
Sanofi Other, Consulting.
Tubulis Other, Consulting.
Urogen Other, Consulting.
Merck ).
Cansera Stock, Patent.
Affyimmune Stock.
Indee Bio Stock.
Amgen Stock.
Johnson & Johnson Stock.